Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3401340 | 0.80 | CYP1A2 (0.56) | CYP1A2TDP1KDM4ESMN1; SMN2PIK3CD | |
| SCHEMBL24010073 | 0.76 | CYP1A2 (0.52) | CYP1A2TDP1KDM4ESMN1; SMN2PIK3CD | |
| SCHEMBL3401349 | 0.75 | CYP1A2 (0.56) | CYP1A2TDP1KDM4ESMN1; SMN2PIK3CD | |
| SCHEMBL23987209 | 0.75 | CYP1A2 (0.56) | CYP1A2TDP1KDM4ESMN1; SMN2PIK3CD | |
| SCHEMBL16362659 | 0.73 | CYP1A2 (0.48) | CYP1A2TDP1KDM4ESMN1; SMN2PIK3CD | |
| SCHEMBL37407 | 0.73 | — | — | |
| SCHEMBL860793 | 0.73 | CYP1A2 (0.77) | CYP1A2TDP1KDM4ESMN1; SMN2PIK3CD | |
| SCHEMBL14407779 | 0.73 | CYP1A2 (0.77) | CYP1A2TDP1KDM4ESMN1; SMN2PIK3CD | |
| SCHEMBL13040144 | 0.71 | CYP1A2 (0.46) | CYP1A2TDP1KDM4ESMN1; SMN2PIK3CD | |
| SCHEMBL14173462 | 0.71 | CYP1A2 (0.58) | CYP1A2TDP1KDM4ESMN1; SMN2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486975-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK CANADA INC. (CA) | 2013-07-16 | — | — | US | disclosed |
| US-20110245296-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK CANADA INC. (CA) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245296-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, REV1, POLR2E | CYP1A2 277/4885TDP1 100/4885KDM4E 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.